Overseas Doctors Power the NHS, But Uncertainty Grows January 16, 2026 Medscape reporting and survey data show why doctors are coming to the UK, what it takes to work in the NHS and what’s now pushing many to look elsewhere.
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema January 16, 2026 Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a potentially promising therapeutic option. LumiNE is part of Almirall’s ongoing lifecycle management activities to enable more patients to benefit from advanced treatments - such as Lebrikizumab - targeting patients with dermatological conditions and high unmet medical needs. The phase III study will be initiated within the first half of 2026 and will evaluate the efficacy, safety, and tolerability of lebrikizumab in at least 270 patients with nummular eczema in Europe for up to 48 weeks of treatment.
Gravity Doesn’t Stand A Chance January 16, 2026 Rimmel London & Red Bull Deliver Gravity Defying Lashes & Thrilling Beam Routine Stunt Beauty brand Rimmel London has joined forces with Red Bull to launch the new Rimmel Thrill Seeker Mega Lift Mascara, taking a collegiate athlete to new heights with lashes lifted from every angle. In Red Bull’s first partnership with Rimmel London, Lily Smith takes on the gravity-defying challenge with confidence and style, and lashes as bold as her routine. The beautifully bold gymnastic balance beam routine was set 52 stories above the streets, which gave Red Bull gymnast Lily Smith wings to reach new heights!
Accertify Appoints CEO and Expands Executive Team to Fuel Next Phase of Growth January 16, 2026 Greg Dukat appointed CEO as Accertify builds leadership depth to accelerate go-to-market execution
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference January 16, 2026 Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026. Almirall’s sustained trajectory of growth and profitability enables the company to reach more patients and supports a growth outlook of double-digit net sales through 2030, combined biologics peak sales of approximately €800 MM (Ebglyss® and Ilumetri®), and a 25% EBITDA margin by 2028. Almirall's leadership in medical dermatology, biologics growth, and continued strong performance of its broad product portfolio fuel advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need.
Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure January 16, 2026 Alpaca appoints lead investor Drive Capital’s Co-Founder and Partner Chris Olsen to its board
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis January 16, 2026 TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo [...]
SOLUM Unveils Large-Format E-Paper Display Lineup at NRF 2026 ‘Evolving into a Global Retail Platform’ January 16, 2026 Expanding large-format E-Paper lineup from 25.3 to 32 inches with advanced control features optimized for premium retail environments Building 'Open Ecosystem' with global partners including Simbe, Competera, and Upshop to eliminate vendor lock-in Bringing 'Retail in Sync' vision to life through live demonstration of integrated solutions at NRF 2026
Goldman Sachs leads Wall St boom amid trading frenzy and deal-making January 16, 2026 Wall Street giants were riding high following this week’s round of earnings updates after months market volatility and deal-making helped take trading revenue to record highs. Goldman Sachs led the surge pocketing $4.3bn in equities trading revenue in the last three months of the year – a record for Wall Street banks. Meanwhile, the banks [...]
European Enterprises Accelerate Responsible AI Adoption January 16, 2026 Organizations in Europe move beyond experimentation, embedding analytics and AI into core operations under strong governance, ISG Provider Lens® report says